Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 5/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928975 | 0.91 | GRM4 (0.49) | GRM4JAK2MEN1KMT2AALDH1A1 | |
| SCHEMBL1415081 | 0.84 | GRM4 (0.46) | GRM4JAK2MEN1KMT2AMET | |
| SCHEMBL3362693 | 0.83 | MEN1 (0.56) | GRM4MEN1KMT2AALDH1A1MAOB | |
| SCHEMBL15516835 | 0.81 | CNR2 (0.52) | GRM4KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL11816831 | 0.77 | KDM4E (0.50) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL1414977 | 0.76 | MET (0.57) | GRM4MEN1KMT2AMETALDH1A1 | |
| SCHEMBL2924155 | 0.74 | MAPT (0.48) | GRM4MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL14735046 | 0.74 | PARP1 (0.50) | MEN1KMT2AALDH1A1KDM4EMAOA | |
| SCHEMBL2295466 | 0.73 | MET (0.49) | JAK2METMAOB | |
| SCHEMBL14204158 | 0.72 | CA12 (0.65) | ALDH1A1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-07-23 | — | — | US | disclosed |
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-07-23 | — | — | US | disclosed |
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-07-23 | — | — | US | disclosed |
| WO-2014033448-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | RESPIVERT LIMTED (GB) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | SYK, FYN, MAPK1 | GRM4 3931/4885JAK2 100/4885MEN1 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.